CRLF2 and leukemia: Engrafted PDX mice were treated with TSLPRCART (2.5e6) to induce leukemia remission, then re-challenged 21 days later with TSLPR+/CRLF2+ALL121 cells without or with concomitant ruxolitinib treatment.